Try our beta test site
15 studies found for:    laquinimod
Show Display Options
Rank Status Study
1 Active, not recruiting A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Laquinimod
2 Completed Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis
Condition: Lupus Arthritis
Interventions: Drug: Laquinimod;   Other: Placebo
3 Active, not recruiting A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
Condition: Relapsing Multiple Sclerosis (RMS)
Intervention: Drug: Laquinimod
4 Completed Laquinimod Phase IIa Study in Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Laquinimod;   Other: placebo
5 Completed Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
Interventions: Drug: Laquinimod;   Other: Placebo
6 Completed A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together
Conditions: Pharmacokinetics;   Pharmacodynamics
Interventions: Drug: laquinimod;   Drug: Placebo
7 Completed A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: laquinimod 0.3;   Drug: laquinimod 0.6;   Other: Placebo
8 Active, not recruiting An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: laquinimod
9 Active, not recruiting A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Placebo
10 Recruiting A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod
Condition: Huntington's Disease
Interventions: Drug: Laquinimod;   Drug: Placebo
11 Completed Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: laquinimod;   Drug: Mycophenolate Mofetil;   Drug: prednisolone/prednisone;   Drug: Placebo
12 Active, not recruiting The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg;   Drug: Matching Placebo;   Drug: Laquinimod 1.2 mg
13 Withdrawn A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Avonex®
14 Completed BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Condition: Multiple Sclerosis
Interventions: Drug: laquinimod;   Drug: placebo;   Drug: Interferon β-1a (Avonex®)
15 Withdrawn A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Laquinimod 0.6;   Drug: Laquinimod 1.2;   Other: Glatiramer Acetate or interferon-beta+ Placebo

Study has passed its completion date and status has not been verified in more than two years.